Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26740556 | 0.92 | CRBN (0.56) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL27290606 | 0.87 | CRBN (0.59) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL26474056 | 0.86 | CRBN (0.53) | CRBNCSNK1A1IKZF2GSPT1 | |
| SCHEMBL26091605 | 0.85 | CRBN (0.63) | CRBNCSNK1A1GSPT1MAP1LC3B | |
| SCHEMBL26456733 | 0.84 | CRBN (0.57) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL30484267 | 0.84 | CRBN (0.57) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL26739474 | 0.84 | CRBN (0.57) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL26748087 | 0.84 | CRBN (0.53) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL26739443 | 0.83 | CRBN (0.55) | CRBNIKZF3CSNK1A1IKZF2GSPT1 | |
| SCHEMBL29739425 | 0.83 | CRBN (0.52) | CRBNIKZF3CSNK1A1IKZF2GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | CRBN 221/4885IKZF3 1965/4885CSNK1A1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.